Cohance Lifesciences has announced an investment of INR 230 million and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India.  

Leveraging its expertise in modified nucleosides and locked nucleic acids (LNA), the new facility is designed to support the full transition of these high-value chemistries from lab-scale development to commercial-scale manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics.

Integrated with a pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. This scale, combined with advanced environmental controls including ISO Class 8 clean rooms and RH-controlled areas, is designed to meet the stringent requirements of complex oligonucleotide building block production.   

Customer engagements are already underway, with audits planned in the coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence in CY26.

Vivek Sharma, Executive Chairman, Cohance Lifesciences, said, “Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics.”     

This investment follows the company’s recently announced USD 10 million expansion of cGMP bioconjugation capabilities at NJ Bio in the United States. Together, these investments form part of Cohance’s planned capacity expansion program across highgrowth modalities, enhancing its ability to serve global innovators from early development to commercial supply.  

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Leveraging a combined platform with state-of-the-art facilities in India and the US, Cohance delivers integrated solutions from early development to commercial supply for leading global pharma companies.

In FY25, revenue was INR 26 billion (approximately USD 313 million) with 33.6 percent adjusted EBITDA margins, with the CDMO business—driven largely by its commercial partnerships with global innovators.